4//SEC Filing
CorMedix Inc. 4
Accession 0001638599-16-000929
$CRMDCIK 0001410098operating
Filed
May 25, 8:00 PM ET
Accepted
May 26, 4:14 PM ET
Size
23.3 KB
Accession
0001638599-16-000929
Insider Transaction Report
Form 4
CorMedix Inc.CRMD
Duffy Matthew
Director
Transactions
- Award
Phantom Stock
2016-05-13+1,153→ 1,153 totalExercise: $0.00→ Common Stock, $0.001 par value per share (1,153 underlying) - Exercise of In-Money
Common Stock, $0.001 par value per share
2016-05-24$0.40/sh+21,454$8,582→ 74,677 total - Exercise of In-Money
Warrant (right to purchase Common Stock)
2016-05-24−25,000→ 0 totalExercise: $0.40From: 2012-11-13Exp: 2017-11-13→ Common Stock, $0.001 par value per share (25,000 underlying)
Holdings
- 5,000
Stock Option (right to buy)
Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (5,000 underlying) - 1,653
Phantom Stock
Exercise: $0.00→ Common Stock, $0.001 par value per share (1,653 underlying) - 150,000
Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (150,000 underlying) - 100,000
Stock Option (right to buy)
Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (100,000 underlying) - 125,000
Stock Option (right to buy)
Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (125,000 underlying) - 15,000
Stock Option (right to buy)
Exercise: $0.28Exp: 2021-11-21→ Common Stock, $0.001 par value per share (15,000 underlying) - 594
Phantom Stock
Exercise: $0.00→ Common Stock, $0.001 par value per share (594 underlying) - 50,000
Stock Option (right to buy)
Exercise: $5.62Exp: 2025-03-01→ Common Stock, $0.001 par value per share (50,000 underlying) - 30,000
Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying) - 75,000
Stock Option (right to buy)
Exercise: $1.91Exp: 2026-02-21→ Common Stock, $0.001 par value per share (75,000 underlying)
Footnotes (9)
- [F1]Does not represent a sale in the market; represents the cashless exercise through the forfeiture of shares to the Issuer to pay the purchase price of the shares acquired upon conversion of the warrant.
- [F2]These options vested 100% on January 10, 2014.
- [F3]These options vest in full on the first anniversary of the date of grant.
- [F4]These options vest quarterly over two years.
- [F5]These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- [F6]On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
- [F7]The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- [F8]Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo
- [F9]These shares were credited automatically to the reporting person's account pursuant to the reporting person's election to defer the receipt of cash compensation of director's fees.
Documents
Issuer
CorMedix Inc.
CIK 0001410098
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001410098
Filing Metadata
- Form type
- 4
- Filed
- May 25, 8:00 PM ET
- Accepted
- May 26, 4:14 PM ET
- Size
- 23.3 KB